- EMD Millipore Releases New, More Powerful MILLIPLEX® Analyst Software for Luminex® Assays
Product News: EMD Millipore Releases New, More Powerful MILLIPLEX® Analyst Software for Luminex® AssaysEMD Millipore, the life science division of Merck KGaA of Darmstadt, Germany, today released MILLIPLEX® Analyst 5.1 for analysis and interpretation of Luminex® bead-based assay results. The new release, developed exclusively for EMD Millipore by VigeneTech, Inc. (Carlisle, MA), includes unique features such as autofit and potency calculation and offers superior quality of data reduction analytics compared to other Luminex® software packages. Superior algorithms yield better data at the low- and high-end of the standard curve. The autofit feature saves time by automatically using the best curve fit method for the curve presented. The potency calculation feature compares two or more standard curves, giving researchers a choice when reducing their data.
Data acquisition and analysis integrates seamlessly with all Luminex® instruments, including MAGPIX®, Luminex 200™ and FLEXMAP 3D® systems. MILLIPLEX® Analyst 5.1 is available as one-, five- and ten-seat licenses, enabling complete flexibility for small, medium, and large laboratories.
MILLIPLEX® Analyst 5.1 is accessed using a code flash drive making it possible to use the software on multiple systems. More user-friendly plate set-up means there are no limitations to where the standard curve can be put on the plate. Other software requires the standard curve to be placed vertically in the first column.
"MILLIPLEX® Analyst 5.1 software delivers a new level of data analysis for bead-based multiplex assays," describes John Sweeney, Head of the Bioscience Business Unit. "New features and increased ease-of-use enable faster, more effective data analysis and interpretation which further enhances the power and utility of multiplex assays. And with the relational database, researchers can compare standard curves and data over a period of time, not just from one particular day's work."